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A B S T R A C T
Background: The rise in the number of patients with arthritis coupled with understaffing of
medical services has seen the deployment of Clinical Nurse Specialists in running nurse-
led clinics alongside the rheumatologist clinics. There are no systematic reviews of nurse-
led care effectiveness in rheumatoid arthritis. Few published RCTs exist and they have
shown positive results for nurse-led care but they have several limitations and there has
been no economic assessment of rheumatology nurse-led care in the UK.
Objective: This paper outlines the study protocol and methodology currently being used to
evaluate the outcomes and cost effectiveness for patients attending rheumatology nurse-
led clinics.
Design and methods: A multi-centred, pragmatic randomised controlled trial with a non-
inferiority design; the null hypothesis being that of ‘inferiority’ of nurse-led clinics
compared to physician-led clinics. The primary outcome is rheumatoid arthritis disease
activity (measured by DAS28 score) and secondary outcomes are quality of life, self-
efficacy, disability, psychological well-being, satisfaction, pain, fatigue and stiffness. Cost
effectiveness will be measured using the EQ-5D, DAS28 and cost profile for each centre.
Power calculations: In this trial, a DAS28 change of 0.6 is considered to be the threshold for
clinical distinction of ‘inferiority’. A sample size of 180 participants (90 per treatment arm)
is needed to reject the null hypothesis of ‘inferiority’, given 90% power. Primary analysis
will focus on 2-sided 95% confidence interval evaluation of between-group differences in
DAS28 change scores averaged over 4 equidistant follow up time points (13, 26, 39 and 52
weeks). Cost effectiveness will be evaluated assessing the joint parameterisation of costs
and effects.
Results: The study started in July 2007 and the results are expected after July 2011.
Trial registration: The International Standard Randomised Controlled Trial Number
ISRCTN29803766.
 2011 Elsevier Ltd. 
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What is already known about this topic?
 In the UK, Rheumatology Clinical Nurse Specialists
conduct nurse-led clinics which provide follow-up care
to patients with rheumatoid arthritis including monitor-
ing, patient education and psychosocial support.
 Research has shown positive outcomes of nurse-led
clinics but the UK studies have several limitations and
lack generalisability and evidence of cost-effectiveness.
What this paper adds
 This paper outlines a protocol and methodology of a
randomised controlled trial being conducted to demon-
strate the outcomes and cost-effectiveness of nurse-led
care in rheumatoid arthritis.
 This is the first UK multi-centred RCT of effectiveness of
nurse-led care in rheumatology.
 This is the first UK study of cost-effectiveness of nurse-
led care in rheumatology.
1. Background
During the past 20 years the rise in the number of
patients with arthritis, understaffing of medical services
and reduced junior hospital doctors’ working hours have
prompted the rheumatology community in the United
Kingdom (UK) to reassess how patient services are
provided. These pressures have meant that whilst essential
medical provision remains intact, it is often at the expense
of the psychological, social, rehabilitative and educational
needs that are so necessary to enhance patient outcomes
(Mounce and Ryan, 2001). To counter these problems,
rheumatology units increasingly augment the multidisci-
plinary team with clinical nurse specialists who are senior
nurses, specially trained to undertake extended roles. By
taking on some of the technical and patient management
activities that were previously the sole responsibility of
rheumatologists, these nurses allow rheumatologists to
concentrate on the more complex tasks such as differential
diagnosis for which they are uniquely trained (Bird, 1983).
Despite this innovative development, the evidence of
effectiveness of nurse-led rheumatology clinics is
limited. Our literature search produced no systematic
review of nurse-led care effectiveness in rheumatology.
Yet there were several systematic reviews of effective-
ness in other chronic diseases such as diabetes (Carey
and Courtenay, 2007), coronary heart diseases (Page
et al., 2005) and chronic obstructive pulmonary disease
(Sridhar et al., 2008). Our recent review (Ndosi et al.,
2010) revealed seven randomised controlled trials
(RCTs) of effectiveness of nurse-led care in rheumatol-
ogy; four of which were in rheumatoid arthritis (Hill
et al., 1994, 2003; Ryan et al., 2006; Tijhuis et al., 2003),
two in osteoarthritis (Hill et al., 2009; Victor et al., 2005)
and one in fibromyalgia (Kroese et al., 2008). In addition
there was an economic evaluation of nurse-led care in
rheumatoid arthritis (Van Der Hout et al., 2003). Of the
seven RCTs of effectiveness, two were from The Nether-
lands and five were from the UK. The Dutch team also
undertook the economic evaluation.
The majority of the RCTs were in rheumatoid arthritis as
this is the disease that the majority of nurses are involved
with. The outcomes of patients under nurse-led care were
compared to those of the rheumatologist (Hill et al., 1994,
2003), in-patient team and day-patient team care (Tijhuis
et al., 2003) and staff nurse working under a rheumatol-
ogist (Ryan et al., 2006). The primary outcomes in these
studies were disease activity, functional status, health
status and coping with rheumatoid arthritis. The results of
disease activity showed that the effects of nurse-led care
were not significantly different from those of the
comparators (Hill et al., 1994, 2003; Tijhuis et al., 2003)
and in one study nurse-led care had better effects on
disease activity (Ryan et al., 2006). The effects of nurse-led
care on functional status were not different from those of
in-patient team or day-patient team care (Tijhuis et al.,
2003). Nurse-led care demonstrated better effects than
standard care on health status and coping with rheumatoid
arthritis (Ryan et al., 2006). The economic analysis (Van
Der Hout et al., 2003) concluded that nurse-led care
provided equivalent quality of life and utility at a lower
cost.
The osteoarthritis RCTs demonstrated better nurse-led
care effects in pain control (Hill et al., 2009) and no
difference in coping with arthritis (Victor et al., 2005). In
diagnosing fibromyalgia, nurse-led diagnosis showed
excellent agreement with that of the rheumatologist and
this agreement was maintained over 24 months (Kroese
et al., 2008).
Despite showing positive results, the RCTs of effective-
ness of nurse-led care in rheumatoid arthritis have several
limitations. The Dutch study (Tijhuis et al., 2003) was the
only multicentre study but it did not compare like with like
as there was a disparity in favour of day care and in-patient
treatments in the number of visits, hours of treatment and
intensity of care. Also, the nurse-led care cohort was less
impaired and had a better quality of life at the start of the
study, making it more difficult to demonstrate a significant
difference between the groups on completion. The
sequential studies undertaken in Leeds (Hill et al., 1994,
2009, 2003) and Stoke-On-Trent (Ryan et al., 2006) are the
only work to date that validates nurse-led rheumatology
clinics in the UK. Unfortunately, the Leeds studies also have
their limitations, as all were undertaken in one clinic
managed by the same rheumatology nurse, one consultant
rheumatologist and four junior doctors. In addition, the
sample sizes were small and there is no confirmation that
these results are reproducible from other nurse-led clinics
in the UK. Finally, there has been no economic assessment
of nurse-led rheumatology clinics in the UK and so we do
not know if they are economically effective.
The aims of this study are to establish whether nurse-
led rheumatology clinics are clinically effective and cost
effective for patients with rheumatoid arthritis.
2. Methods
2.1. Study design
This is a pragmatic trial in a complex clinical environ-
ment and is conducted over 4 years as a multi-centred RCT.
M. Ndosi et al. / International Journal of Nursing Studies 48 (2011) 995–1001996
Fig. 1. Study design.
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Patients are randomised using an office hours remote secure
telephone randomisation service provided by the Clinical
Trials and Research Unit, University of Leeds. Patients who
fulfil the eligibility criteria and have provided written
informed consent are randomised on a 1:1 basis to either
Nurse-led clinic (experimental group) or a rheumatologist-
led clinic (control group). Randomisation is by random
permuted blocks, using the stratification factors, centre and
DAS28 score (low 3.2 or moderate to severe >3.2) at
baseline. After recruitment, patients have 5 follow-up visits
over 12 months. (Fig. 1). The methods are consistent with
current guidelines on design, conduct and analysis of
pragmatic randomised clinical trials (Moher et al., 2010;
Ramsey et al., 2005; Schulz et al., 2010; Zwarenstein et al.,
2008), and those explicitly for non-inferiority trials (Bos-
mans et al., 2008; Piaggio et al., 2006).
2.2. Study population
The study comprises 180 patients with rheumatoid
arthritis recruited from 10 rheumatology centres
throughout the UK. Patients with both stable and active
disease are included as this reflects the practice of clinical
nurse specialists in the UK and Europe and so make the
results more meaningful. All patients are seen in one of the
10 participating centres. The centres are distributed
throughout the UK and this provides a socio-demographic
mix of patients. Inclusion criteria are: a positive diagnosis
of rheumatoid arthritis as defined by the American
Rheumatism Association (Arnett et al., 1988); aged 18
years or above, and ability to complete questionnaires
unaided. Exclusion criteria are: patients unwilling to be
randomised to a nurse-led clinic or rheumatologist-led
clinic; patients suffering from unstabilised concomitant
disease; patients awaiting surgery and patients who have
already received care from the practitioners involved in
the study.
2.3. Hypothesis
The hypothesis is that the outcomes from nurse-led
clinics will not be inferior to those obtained by the
rheumatologist-led clinics, but at a lower cost and greater
patient satisfaction.
3. Interventions
Following randomisation, patients are given appoint-
ments with their respective practitioners for weeks 0, 13,
26, 39 and 52. When patients arrive at the clinic, they are
seen by an independent assessor who oversees the
completion of pain Visual Analogue Scale (VAS), fatigue
VAS, the length of morning stiffness and performs joint
counts for Disease Activity Score (DAS28). The indepen-
dent assessor also gives the patient their blood form,
questionnaires in a freepost return envelope and sends
them to the waiting area ready to see their allocated
practitioner. The joint examination for DAS28 can be prone
to inter-observer variation and training or agreement
sessions have been shown to minimise this (Grunke et al.,
2010; Scott et al., 1996). Therefore a training session was
conducted (by MN) with the independent assessors at the
study set-up meeting to ensure standardisation. The joint
examination technique was based on the European League
Against Rheumatism handbook of clinical assessment in
rheumatoid arthritis (van Riel and Scott, 2000). Since this is
a pragmatic trial, the practitioners in both arms of the trial
(Clinical Nurse Specialists and the Rheumatologists) did
not receive any more training; they manage their patients
according to their normal practice.
During the consultation, the clinical nurse specialists
record their interventions in a standard ‘‘consultation
checklist’’ especially designed for this study. The nurse-led
care interventions may include: pain control, medication
and dosage changes, intra-articular or intra-muscular
steroid injections, provision of patient education or
psychosocial support, prescription of splints, non-protocol
blood tests or radiographic examination. Other interven-
tions such as referral to the admission ward, to the
rheumatologist, physiotherapists, podiatrist or any other
health care professional may be carried out as appropriate.
The referrals, conferrals and the length of consultation are
also recorded.
Patients randomised to the rheumatologist-led care
(control group) also have the same number of study visits
and the rheumatologist provides care as per normal
practice noting all the interventions and referrals in the
consultation checklist.
4. Outcome measures
4.1. Primary and secondary outcomes
The primary outcome measure is the DAS28 (Prevoo
et al., 1995), an internationally recognised measurement of
disease activity in rheumatoid arthritis. It is a composite
measurement comprising objective (number of swollen
joints and erythrocyte sedimentation rate [ESR] or C-
reactive protein [CRP]) and subjective (number of tender
joints and patients global assessment) indices. DAS28 score
has been shown to be a strong predictor of physical
disability and radiological progression and a sensitive
discriminator between patients with high and low disease
activity (Prevoo et al., 1996; van Gestel et al., 1998). DAS28
score is widely used in making decisions about treatment
effectiveness and it forms the basis for the European League
against Rheumatism response criteria for rheumatoid
arthritis (Van Gestel et al., 1996). Scores can range from 0
to 9.4, assuming that an ESR of 100 is taken as the upper
limit. Levels of disease activity are defined as DAS28 3.2
mild; DAS28 >3.2 and 5.1 moderate; DAS28 >5.1 severe
(van Gestel et al., 1998; Van Gestel et al., 1996). The DAS28
will be measured at baseline and 13, 26, 39 and 52 weeks.
Secondary measures include haematological, clinical
and questionnaire data. The haematological and clinical
measures comprise: CRP or ESR, pain intensity (using
10 cm VAS), duration of morning stiffness (hours/minutes)
and Fatigue (10 cm VAS). The following questionnaires will
be administered at baseline, 26 and 52 weeks:
 Health Assessment Questionnaire (Kirwan and Reeback,
1986)
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 Hospital Anxiety and Depression Scale (Zigmon and
Snaith, 1983)
 Leeds Satisfaction Questionnaire (Hill et al., 1992)
 The Arthritis Self Efficacy Scale (Lorig et al., 1989)
 Rheumatoid Arthritis Quality of Life Questionnaire (De
Jong et al., 1997)
An additional questionnaire, the EQ-5D (The Euroqol
group, 1990) will be completed at baseline and weeks 13,
26, 39 and 52 to provide health data for the economic
analysis
4.2. Power calculations
A change in DAS28 score of 1.2 or more is deemed a
clinically significant improvement, and a change of 0.6 or
more reflects a moderate improvement (van Riel et al.,
1996). A change in DAS28 score of 0.6 is assigned as the
‘inferiority’/’non-inferiority’ margin. Thus:
Null hypothesis (inferiority): mean DDAS28RLC mean
DDAS28NLC 0.6.
Alternative hypothesis (non-inferiority): mean
DDAS28RLC mean DDAS28NLC< 0.6.
Where D = change in, RLC = Rheumatologist-led clinic
and NLC = Nurse-led clinic.
A total sample size of 180 participants (90 per
treatment arm) is needed to reject the null hypothesis of
‘inferiority’, given 90% power and 1-sided statistical testing
with 2.5% significance level (and a pre-hypothesized
standard deviation in DAS28 change scores of 1.5). This
total sample size assumes a 10% drop out/non-response
rate. The calculation is based on a repeated-measures
(pooled) analysis of between-group differences averaged
over 4 equidistant follow up time points (13, 26, 39 and 52
weeks). The sample size calculation assumes that the intra-
class correlation coefficient (for the correlation of observa-
tions over time within individuals) will be about 0.5.
5. Statistical analysis
5.1. Statistical analysis
Analyses will be carried out using both intention to
treat and per protocol methods as advocated in extended
CONSORT guidelines (Piaggio et al., 2006). Difference in
mean summary scores will be presented with a 95% two-
sided confidence interval from which we can draw a
conclusion as to whether to accept or reject the null
hypothesis of ‘inferiority’ regarding the nurse-led care
intervention compared to the rheumatologist-led care. The
primary outcome measure (DAS28 change score) and
secondary measures will be compared between the two
groups using data pooled over time; the evaluation
focusing on the comparability of average change in
DAS28 over the assessed follow up period. Secondary
measurement will focus on individual time points.
Analysis will be by hierarchical repeated measures
modelling. Analysis will adjust for age, gender, centre,
baseline DAS28 (and corresponding baseline values for
secondary outcomes). Multiple imputation will be used to
address the issue of missing data (Schafer, 1999). Analysis
will also be carried out investigating outcome in relation to
the interaction of intervention group and specific baseline
variables: age, gender and DAS28.
5.2. Economic evaluation
The economic assessment will encompass both a cost
utility analysis and a cost effectiveness analysis (Bosmans
et al., 2008; Ramsey et al., 2005). A tiered approach to the
evaluation will encompass the following economic per-
spectives: (i) NHS; (ii) healthcare [NHS plus direct patient
costs]; (iii) societal [direct (healthcare) plus indirect
(productivity) costs].
Healthcare resource use, specifically in relation to
rheumatoid arthritis, is derived through clinic audits and
follow up patient questionnaires, and embraces health
professional consultations (primary and secondary care),
hospital admissions (day care, inpatient stays, A&E visits),
investigations, and treatments including over-the-counter
medications. Costs will be derived from sources of
‘national average’ costs (Curtis, 2009; NHS Executive,
2009), and also by direct elicitation from the self-report
questionnaires for private out-of-pocket expenditure on
health care service use, travel, medication, aids and special
dietary requirements. Data collected from each patient on
employment status and job title (classified according to its
socioeconomic classification using the Office of National
Statistics (ONS) approach (ONS, 2000a,b)) will be used to
determine productivity losses using the human capital
approach by multiplying a patient’s reported number of
days off work by the expected average daily wage
extracted from National Statistics survey databases
(ONS, 2004). Multiple imputation will be used to address
missing cost data (Schafer, 1999). Health outcomes will be
assessed through QALYs derived from the EQ-5D for the
cost utility analysis, and the DAS28 change score for the
cost effectiveness analysis (with incremental differences in
cost being evaluated in relation to the non-inferiority
margin of 0.6 in mean DAS28 change).
Between-group economic comparisons will focus on
the joint estimation of incremental costs and effects. The
precision of the estimates will be ascertained by calculat-
ing confidence intervals around effect and cost differences,
derived through adjusted linear regression modelling. Data
for costs are usually right-skewed, and will therefore be
analysed using the preferred bootstrap technique (Heyse
et al., 2001; Lambert et al., 1998; Mullner, 2003).
Uncertainty around the cost-effect estimates will be
shown graphically using cost effectiveness/utility planes
(Briggs and Fenn, 1998). Cost-acceptability curves will be
used to help make informative decisions regarding the
cost-effectiveness of the nurse clinics at variable ceiling
willingness-to-pay cost thresholds (Stinnett and Mullahy,
1998) Sensitivity analyses will establish the robustness of
findings to various assumptions (e.g. imputed versus
complete-case data).
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